Brief: Alligator Bioscience: Grant Awarded To Phase 2/3 Trial With Mitazalimab In Biliary Tract Cancer
08/09/2025 07:46
Sept 8 (Reuters) - Alligator Bioscience AB ATORX.ST: GRANT AWARDED TO INVESTIGATOR-INITIATED PHASE 2/3 TRIAL WITH MITAZALIMAB IN BILIARY TRACT CANCER Source text: ID:nMFNbdRXHY Further company coverage: ATORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsBrief: Alligator Bioscience Q1 Net Loss SEK 1.4 Million
Sweden's Alligator Bioscience posts Q1 net profit, narrows operating loss
Brief: Alligator Bioscience Q1 EBIT SEK -17.8 Million
Brief: Alligator Bioscience Signs LoI With Unicancer For Phase 3 Mitazalimab Development
Brief: Exercise Of Warrants Brings Alligator Bioscience Net Proceeds Of SEK 12 Mln